DE60138722D1 - Orale zubereitungen mit vorteilhaften zerfallseigenschaften - Google Patents

Orale zubereitungen mit vorteilhaften zerfallseigenschaften

Info

Publication number
DE60138722D1
DE60138722D1 DE60138722T DE60138722T DE60138722D1 DE 60138722 D1 DE60138722 D1 DE 60138722D1 DE 60138722 T DE60138722 T DE 60138722T DE 60138722 T DE60138722 T DE 60138722T DE 60138722 D1 DE60138722 D1 DE 60138722D1
Authority
DE
Germany
Prior art keywords
water
carmellose
sodium
disintegrant
granule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138722T
Other languages
English (en)
Inventor
Kazuyuki Fujihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18771855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60138722(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Application granted granted Critical
Publication of DE60138722D1 publication Critical patent/DE60138722D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
DE60138722T 2000-09-22 2001-09-14 Orale zubereitungen mit vorteilhaften zerfallseigenschaften Expired - Lifetime DE60138722D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000288234 2000-09-22
PCT/JP2001/007983 WO2002024166A1 (fr) 2000-09-22 2001-09-14 Preparations orales dotees de bonnes caracteristiques de desagregation

Publications (1)

Publication Number Publication Date
DE60138722D1 true DE60138722D1 (de) 2009-06-25

Family

ID=18771855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138722T Expired - Lifetime DE60138722D1 (de) 2000-09-22 2001-09-14 Orale zubereitungen mit vorteilhaften zerfallseigenschaften

Country Status (11)

Country Link
US (1) US7727553B2 (de)
EP (2) EP1974724A3 (de)
JP (1) JP4868695B2 (de)
AT (1) ATE431136T1 (de)
AU (1) AU2001286237A1 (de)
CA (2) CA2824077C (de)
DE (1) DE60138722D1 (de)
DK (1) DK1327440T5 (de)
ES (1) ES2325764T3 (de)
TW (2) TWI289062B (de)
WO (1) WO2002024166A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
EP1637530A4 (de) * 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co Therapeutisches mittel für senile demenz
JP4847320B2 (ja) 2004-02-20 2011-12-28 大日本住友製薬株式会社 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法
WO2006123678A1 (ja) * 2005-05-18 2006-11-23 Dainippon Sumitomo Pharma Co., Ltd. ドロキシドパを含有する安定な錠剤
PT1884242E (pt) 2005-05-26 2013-05-21 Dainippon Sumitomo Pharma Co Composição farmacêutica compreendendo lurasidona
JP4866349B2 (ja) * 2005-06-13 2012-02-01 大日本住友製薬株式会社 可溶化型製剤
KR20130016386A (ko) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
JPWO2007018190A1 (ja) * 2005-08-10 2009-02-19 塩野義製薬株式会社 苦味抑制製剤
EP1973531A2 (de) * 2006-01-02 2008-10-01 Rubicon Research Private Limited Pharmazeutische zusammensetzungen
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
ES2633449T3 (es) 2007-10-31 2017-09-21 Johnson & Johnson Consumer Inc. Forma de dosis oralmente desintegrable
EP2251012A4 (de) 2008-02-11 2013-03-06 Dainippon Sumitomo Pharma Co Tablette mit verbesserten elutionseigenschaften
US9119820B2 (en) 2008-06-13 2015-09-01 Sumitomo Dainippon Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
CN104321013B (zh) 2012-03-21 2017-08-15 皇家飞利浦有限公司 用于基于ecg信号来提供睡眠质量的视觉表示的方法和装置
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) * 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9597291B2 (en) * 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
JP6037824B2 (ja) * 2012-12-28 2016-12-07 ライオン株式会社 エトドラク含有固形製剤
WO2015105992A1 (en) 2014-01-10 2015-07-16 Mcneil-Ppc, Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
US10966928B2 (en) 2016-03-25 2021-04-06 Universiteit Gent Oral dosage form
BR112018069440A2 (pt) 2016-03-25 2019-02-12 Univ Gent forma de dosagem oral
WO2017170858A1 (ja) 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
CN109640996A (zh) * 2016-08-31 2019-04-16 大日本住友制药株式会社 水性悬浮型制剂
WO2018130943A1 (en) 2017-01-11 2018-07-19 Piramal Enterprises Limited Oral pharmaceutical composition of lurasidone and preparation thereof
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
WO2023078366A1 (zh) * 2021-11-04 2023-05-11 上海博志研新药物技术有限公司 一种盐酸鲁拉西酮口溶膜组合物、其制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148114A (ja) * 1984-11-15 1986-07-05 Teijin Ltd ニフエジピンの顆粒剤
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
JPH04305526A (ja) * 1991-03-28 1992-10-28 Morishita Roussel Kk 薬剤組成物
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
HUP0100469A2 (hu) 1997-12-19 2001-08-28 Smithkline Beecham Corporation Eljárás harapással diszpergálható tabletták előállítására
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
JP4438121B2 (ja) 1998-04-27 2010-03-24 大正製薬株式会社 口腔内速崩錠及びその製造方法
KR100267576B1 (ko) * 1998-07-25 2000-11-01 허계성 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법
JP2000086503A (ja) * 1998-09-07 2000-03-28 Pola Chem Ind Inc 錠剤医薬組成物
JP2000086509A (ja) 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation

Also Published As

Publication number Publication date
EP1327440B1 (de) 2009-05-13
TWI289063B (en) 2007-11-01
US7727553B2 (en) 2010-06-01
EP1327440A4 (de) 2006-02-01
AU2001286237A1 (en) 2002-04-02
EP1327440A1 (de) 2003-07-16
TWI289062B (en) 2007-11-01
EP1974724A2 (de) 2008-10-01
US20040028741A1 (en) 2004-02-12
CA2424001A1 (en) 2003-03-20
ES2325764T3 (es) 2009-09-16
ATE431136T1 (de) 2009-05-15
DK1327440T3 (da) 2009-06-08
JP4868695B2 (ja) 2012-02-01
CA2824077C (en) 2016-01-26
CA2824077A1 (en) 2002-03-28
CA2424001C (en) 2013-10-22
JPWO2002024166A1 (ja) 2004-01-29
WO2002024166A1 (fr) 2002-03-28
DK1327440T5 (da) 2009-09-07
EP1974724A3 (de) 2008-11-12
TW200524642A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
DE60138722D1 (de) Orale zubereitungen mit vorteilhaften zerfallseigenschaften
EP1884242A4 (de) Pharmazeutische zusammensetzung
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
EE05022B1 (et) Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
NO993315L (no) Raskt frigjörende og smaksmaskerende farmasöytisk doseringsform
DE69311395D1 (de) Sphäroidische Arzneimittelformulierung
BG106870A (en) Glyburide composition
NO20060786L (no) Farmasoytiske preparater med oppsvulmbart belegg
DE69908626D1 (de) Orale kombination von lufenuron und nitenpyram gegen flöhe
RU96116411A (ru) Быстро распадающаяся готовая препаративная форма трамадола или соли трамадола
DE60233552D1 (de) Fenofibrattabletten
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
TR200202557T1 (tr) Esmolol formülasyonu
EP1645273A3 (de) Neue Verwendung von (R)-(-)-2-(5-(4-Fluorophenyl)-3-Pyridylmethylaminomethyl)-Chromane und ihrer physiologisch verträglichen Salze
NO20033855D0 (no) Fremgangsmåte ved fremstilling av farmasöytiske tabletter inneholdende paroxetinhydrokloridanhydrat
AU7547100A (en) Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
NO174198C (no) Analogifremgangsmåte for fremst.av den terapeutisk aktive forbindelse 3-metoksy-4-(1-metyl-5-(2-metyl-4,4,4-trifluorbutylkarbamoyl)indol-3-ylmetyl)-N-(2-metylfenyl-sulfonyl)benzamid, eller et farmasöytisk akseptabelt salt derav
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
NO20031030D0 (no) Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
NO20021527D0 (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
RU98114489A (ru) СОСТАВ ИНГИБИТОРА 5α-РЕДУКТАЗЫ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ИСПОЛЬЗОВАНИЕ
ATE319452T1 (de) Arzneimittel gegen essstörungen
TH45760B (th) สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก

Legal Events

Date Code Title Description
8364 No opposition during term of opposition